Richard G. Harris, MD, President of LUGPA and UroPartners, discusses the recent incorporation of advanced prostate cancer (APC) clinics amongst LUGPAs within the United States. He goes on to discuss why APC clinics are important, clinical trials for m0, m1, and castrate sensitive prostate cancer, as well as the importance of genetic testing within an APC clinic.
Read More
Evan R. Goldfischer, MD, MBA, Co-Founding CEO and Founding Director of Research for Premier Medical Group of the Hudson Valley, discusses how those managing clinical research programs must adapt to new pressures in 2020. He notes that the increases in regulation and FDA oversight are challenges. He also details the necessary structure of research departments and processes for budget negotiation. By also describing possible pitfalls of clinical research programs, Dr. Goldfischer gives an encompassing overview of the process of clinical research program management.
Read More
A. Karim Kader, MD, PhD, FRCSC, Professor in the Department of Urology and Director of Urologic Oncology at the University of California, San Diego, argues that genomic risk stratification plays an important role in our understanding of prostate cancer. He highlights the differences between germline and somatic genomic classifiers and the impact they can have on prostate cancer risk and outcome. Dr. Kader discusses the advantages and disadvantages of a wide range of genetic tests. Additionally, he discusses the differences between high penetrance and low penetrance genetic change and the implications they can have on screening, detection, and treatment decisions.
Read MoreMark A. Moyad, MD, MPH, the Jenkins/Pokempner Director of Complementary/Alternative Medicine at the University of Michigan Medical Center in the Department of Urology, discusses the consequences of androgen-deprivation therapy-related skeletal muscle loss. He goes on to discuss the prevalence of sarcopenia in prostate cancer patients, the clinical studies demonstrating the efficacy of incorporating exercise for the prevention or mitigation of sarcopenia, as well as the benefits and limitations of diet and over the counter supplements for the prevention of sarcopenia.
Read More
Priya N. Werahera, PhD, Associate Professor in the Departments of Pathology and Bioengineering at the University of Colorado Anschutz Medical Campus, discusses the presence of bacteria in the prostrate and that next generation sequencing is the best way to identify microbial DNA in post DRE urine samples. He reveals that cutibacterium acnes strain Type II is the most prevalent bacteria found in PCa patients. Finegoldia magna produces equol and is associated with lower risks of prostate cancer. It is still unclear whether a malignant tumor creates an ideal environment for infection, or if a bacterial infection precedes a carcinoma.
Read More